RECENT DISCOVERY: Lipidologist Spotlights Ancient Japanese Enzyme ‐ And How Adults Over 50 Are Dissolving Decades of ‘Artery Glue’ In Just 8 Weeks

An estimated 1 in 4 American adults has a first-degree relative who suffered a heart attack, stroke, or sudden cardiac event before the age of 65.

If you’re one of them, your primary care physician has almost certainly told you what mine told my father:

Watch your cholesterol. Take a statin if you need one. Hope for the best.

For the first decade of my 20-year career in cardiovascular prevention, I practiced the same way.

Then I started noticing a pattern the cholesterol hypothesis couldn’t explain.

Patients in their late 40s and early 50s — fit, non-smokers, clean diets, LDL in the normal range, statins on board for years — were still walking into my office after a cardiac event. Or worse, they weren’t walking in at all.

Every one of them had something in common: a father, brother, uncle, or grandfather who’d died young of the same thing.

And the standard of care — the one I’d been trained to deliver — was missing whatever was actually killing them.

What you’re about to read is the work of the last ten years of my practice. It’s also the reason I’ve changed how I treat every patient who walks in with a family history.

The Framingham Offspring Study is one of the longest-running cardiovascular studies in medical history. It followed the adult children of the original Framingham Heart Study participants for over three decades.

Buried in the data was a finding that should have reshaped how we approach inherited heart disease:

People with a parent who had early cardiovascular disease had roughly double the event risk of the general population — even after researchers statistically controlled for cholesterol, blood pressure, diabetes, weight, and smoking.

In other words, after you remove every traditional risk factor cardiologists measure, family history still independently doubles your risk.

Something else is going on.

A decade of subsequent research — at institutions including Harvard, Johns Hopkins, and several European cardiovascular centers — has converged on the same answer.

That “something else” is a clotting protein called fibrinogen.

When I tell patients this, the reaction is almost always the same:

If this research has been around for 30 years, why has nobody ever mentioned it to me?

The uncomfortable answer has very little to do with medicine.

Cardiology guidelines in the United States are written around treatments that have been through large randomized controlled trials — and those trials overwhelmingly target cholesterol, because that’s where the statin industry funded the research.

Fibrinogen has no blockbuster drug behind it. No company is spending $800 million on a Phase III trial to get a fibrinogen-lowering treatment into guidelines.

And so the test stays off the panel. The risk factor stays unaddressed. And patients with family history keep dying at the same rates their fathers did, on the same medications their fathers took.

This is not a conspiracy. It’s just how the system is built.

But it’s why, if you’re reading this, you’ve probably never had your fibrinogen checked — even though it’s one of the most predictive markers we have for people in your exact situation.

In 1980, a Japanese researcher named Dr. Hiroyuki Sumi, working at the University of Chicago Medical School, was screening hundreds of traditional foods from around the world, looking for compounds that could dissolve fibrin.

When he tested an extract from natto — a pungent fermented soybean dish served at Japanese breakfast tables for centuries — the fibrin clot in his petri dish dissolved in under 18 hours.

For comparison, the standard pharmaceutical clot-dissolving agents available to him at the time took days to achieve the same result.

He named the enzyme nattokinase and published his findings in 1987.

In the four decades since, dozens of independent research teams — primarily in Japan, South Korea, and more recently China and Europe — have replicated and extended Dr. Sumi’s work.

What the literature consistently shows is this:

None of this has made it into U.S. cardiology guidelines. For the same reason fibrinogen testing hasn’t: there’s no pharmaceutical patent behind a fermented Japanese food.

But for patients with a family history of heart disease — patients who by every available measure are under-served by the current standard of care — the implications are difficult to ignore.

Over the last decade, I’ve integrated fibrinogen testing and a standardized nattokinase protocol into my approach for family-history patients. The patterns I’ve seen are consistent. Three cases that illustrate them:

These are not outliers. They are representative of what I see across the subset of my practice that fits the family-history profile.

The protocol doesn’t work equally well for everyone. Some patients see larger drops, some smaller. But the direction of the data is unambiguous, and it’s consistent with what the Japanese literature has been showing for 40 years.

Once I started recommending nattokinase to patients, I ran into a problem I wasn’t expecting.

The clinical studies all used standardized, lab-verified enzyme activity. The supplements on U.S. shelves, for the most part, do not.

Nattokinase potency is measured in fibrinolytic units (FU) — a quantification of actual enzymatic activity, not powder weight. Think of it as the difference between a battery rated by weight versus one rated by charge capacity.

When I sent samples of widely-sold U.S. nattokinase supplements to an independent analytical lab, the results were sobering.

If your supplement fails on any of these, the clinical data I cited above does not apply to what’s actually in your bottle.

After assessing the products available to U.S. consumers, there was one formulation I was willing to recommend to my own patients.

The formulation I use in my practice is called Fernova.

I don’t have a financial relationship with the company that makes it. I recommend it because it meets the clinical threshold the published research actually uses:

I tell my patients the same thing I’m about to tell you. The enzyme is not a stimulant. You should not expect to feel anything dramatic in the first few days. The work is happening at a timescale the bloodstream operates on, not the timescale of a cup of coffee.

Here’s what the typical patient trajectory looks like in my practice:

This is not a miracle cure. I don’t use that language because it’s not honest.

What it is, is the first intervention I’ve found in two decades that directly addresses what the research keeps pointing at — in a population the current standard of care is measurably failing.

The following are unsolicited messages sent to the company from patients who started the protocol after reading similar material. They’re reproduced with permission.

A clinical-grade, third-party-verified nattokinase formula at 4,000 FU per serving would reasonably retail for $59.99 per pack. That’s in line with comparable medical-grade supplements in the cardiovascular prevention space.

For a limited time, the manufacturer is running a new-patient offer that meaningfully lowers the monthly cost:

The protocol in the clinical literature uses 4,000 FU daily for a minimum of 12–16 weeks before re-testing fibrinogen. That’s why I typically point family-history patients toward the 4- or 6-pack bundle — not because more is better, but because consistency across months is what moves the labs.

Every order ships with a 90-day money-back guarantee. If you don’t notice measurable improvement in how you feel — chest tightness, sleep, stair tolerance — within that window, the company refunds in full.

I don’t write articles for the internet often. This is an exception because I’ve watched too many family-history patients come into my office after an event that was, in retrospect, preventable.

The research on fibrinogen has been sitting in peer-reviewed journals for three decades. The research on nattokinase has been replicated in labs on three continents for four decades. The clinical pattern in my own practice is consistent with what both literatures predict.

What’s missing is a pharmaceutical company willing to spend $800 million validating a fermented soybean extract through the FDA process that they can’t patent afterward.

That gap is not going to close. Which means people with family histories will keep dying from conditions we know how to intervene on, because the intervention doesn’t have a drug rep assigned to it.

If you’ve read this far, you now know more about the actual mechanism behind inherited cardiovascular risk than the majority of primary care physicians in the United States.

What you do with that is up to you.

To your heart,

Dr. Michael Kowski, MD
Board-Certified Lipidologist